Corcept Therapeutics, Inc. (CORT)
87.99
+0.86
(+0.99%)
USD |
NASDAQ |
Dec 12, 16:00
88.03
+0.04
(+0.05%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (Quarterly): 68.85M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 1.90B |
| Gilead Sciences, Inc. | 1.334B |
| United Therapeutics Corp. | 127.50M |
| Vertex Pharmaceuticals, Inc. | 977.70M |
| Theravance Biopharma, Inc. | 7.707M |